Evidence map›Paper›PMID 41444940›Full record

ArticleBMC medicine2025

Role of prior HPV infection and CD4 T-cell count in modulating cellular immune responses to a three-dose nonavalent HPV vaccine schedule in PWH receiving ART.

Eeva Tortellini, Mariasilvia Guardiani, Anna Carraro, Lorenzo Ansaldo, Sara Corazza, Sara Giovanna De Maria, Silvia Garattini, Mirko Barresi, Valeria Belvisi, Maria Antonella Zingaropoli and 9 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eeva TortelliniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Mariasilvia GuardianiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. mariasilvia.guardiani@uniroma1.it.
Anna CarraroDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Lorenzo AnsaldoInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Sara CorazzaInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Sara Giovanna De MariaInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Silvia GarattiniInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Mirko BarresiInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Valeria BelvisiInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Maria Antonella ZingaropoliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Federica DominelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Carmen FalvinoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Fabio MengoniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Alessandro TavelliICONA Foundation, Milan, Italy.
Cristina GiambiUOS Profilassi E Sorveglianza Malattie Infettive, SM Goretti Hospital, Latina, Italy.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Cosmo Del BorgoInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Raffaella MaroccoInfectious Diseases Unit, SM Goretti Hospital, Latina, Italy.
Miriam LichtnerDepartment of NESMOS, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost studies on HPV vaccination have focused on the antibody response and on bivalent and quadrivalent vaccines. For these reasons, an evaluation of T-cell responses in PWH on effective ART to the Gardasil 9® vaccine according to prior HPV infection and baseline CD4 T-cell count was performed.

methodsWe prospectively enrolled PWH on effective ART. T-cell responses were assessed by flow cytometry at pre-vaccination (T0), on the same day of the third dose (T1) and 6 months after the third dose (T2) after stimulation with a pool of HPV16 and HPV18 L1 peptide libraries. An evaluation of IFN-γ in supernatants was also carried out. Baseline CD4 T-cell count was defined at the first dose.

resultsAn increase in the percentage of responding and polyfunctional T-cells was found in both HPV - and HPV + groups, with no significant differences between them at any time point. When the population was stratified according to baseline CD4 T-cell count, an increase was found only in > 500 cells/μL group for both the responding and polyfunctional T-cells. Furthermore, a higher frequency of responding CD4 T-cells at T1 (p = 0.0049), a higher frequency of responding CD8 T-cells at T1 and T2 (p = 0.05 and p = 0.02, respectively), a higher frequency of polyfunctional CD4 T-cells at T1 (p = 0.0242) and a higher frequency of polyfunctional CD8 T-cells at T2 (p = 0.02) were found in > 500 cells/μL group than in their relative counterpart. The analysis of the estimated change from T0 revealed no statistically significant differences between PWH with or without prior HPV infection, whereas significant associations between higher CD4 counts and improved immune responses were found.

conclusionsOur study revealed a coordinated T-cell response against HPV16 and 18 after Gardasil9® vaccine in PWH, including those with a history of HPV infection. PWH with a lower CD4 T-cell count remains a group who may not mount a fully protective immune response and, therefore, may require additional protection or ad hoc vaccination strategies. These data reinforce the key role of basal CD4 level in modulating the immune response over time, while prior HPV infection did not significantly affect the rate and quality of the response.

Indexed as

CD4-Positive T-LymphocytesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Immunity, CellularPapillomavirus InfectionsPapillomavirus VaccinesAdultCD4 Lymphocyte CountFemaleHumansMaleMiddle AgedProspective StudiesYoung AdultHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus Vaccines9vHPV vaccineBaseline CD4 T-cell countFlow cytometryHPVPWHT-cell responseVaccination

Identifiers

PMID41444940
PMCPMC12729619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.